Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept
Journal of Enterocolitis · 2023
DOI: 10.14744/jenterocolitis.2023.23050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enterocolitis, 2023. Verfasst von Emin Bodakçı.
Abstract (Originalsprache)
Tumor necrosis factor -alpha is an important cytokine that plays a role in inflammation and immune reactions.Tumor necrosis factor-alpha and its receptors are known to play a role in the pathogenesis of numerous immune-mediated diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.It is known that anti-tumor necrosis factor agents used in inflammation suppression and remission could lead to a series of paradoxical side effects.In this paper, we presented a case with ankylosing spondylitis in whom Crohn's disease developed during etanercept treatment.A significant improvement was achieved in the symptoms and laboratory values by stopping etanercept treatment and switching to adalimumab.
Zitieren
APA
Bodakçı, E. (2023). Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept. Journal of Enterocolitis. https://doi.org/10.14744/jenterocolitis.2023.23050
Vancouver
Bodakçı E. Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept. Journal of Enterocolitis. 2023. doi:10.14744/jenterocolitis.2023.23050
BibTeX
@article{Bodak2023,
author = {Bodakçı, Emin},
title = {Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept},
journal = {Journal of Enterocolitis},
year = {2023},
doi = {10.14744/jenterocolitis.2023.23050}
}
EUVIMED